

1 **Comparison of Early and Intermediate-Term Outcomes Between**
2 **Hybrid Arch Debranching and Total Arch Replacement: A Systematic**
3 **Review and Meta-analysis of Propensity-Matched Studies**
4

5 Naritsaret Kaewboonlert^{1,*}, Worawong Slisatkorn², Apichat Tantraworasin³, Punthiti
6 Pleehachinda⁴, Tossapol Prapassaro², Natthipong Pongsuwan¹, Chanut Chatkaewpaisal⁵,
7 Tummarat Ruangpratyakul⁶
8

9 ¹ School of Surgery, Institute of Medicine, Suranaree University of Technology, Nakhon
10 Ratchasima, Thailand; ² Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol
11 University, Bangkok, Thailand; ³ Department of Surgery, Faculty of Medicine, Chiang Mai
12 University, Chiang Mai, Thailand; ⁴ Department of Surgery, Phra Nakhon Si Ayutthaya Hospital,
13 Phra Nakhon Si Ayutthaya Hospital, Thailand; ⁵ Heart Center, Bangkok Hospital Ratchasima,
14 Nakhon Ratchasima, Bangkok, Thailand; ⁶ Department of Surgery, Roi Et Hospital, Roi Et,
15 Thailand
16

17 * Corresponding author: Naritsaret Kaewboonlert, School of Surgery, Institute of Medicine,
18 Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand. Tel: +66 4422 3956,
19 E-mail: naritcv@gmail.com
20

21 Word Count: 3,922 words
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 Abstract

37

38 **OBJECTIVES:** To systematically review and pool the clinical outcomes of hybrid arch repair
39 (HAR) and total arch replacement (TAR) with or without a frozen elephant trunk for treating aortic
40 arch aneurysms, dissections, or other pathology in propensity score-matched studies.

41 **METHODS:** We conducted electronic database searches in PubMed, Embase, the Cochrane
42 Library, and Google Scholar to identify studies reporting outcomes of HAR versus TAR. Risk of
43 bias was assessed using non-randomized studies of interventions (ROBINS-I) tool. The primary
44 outcome was in-hospital mortality analyzed using a random-effects model to compute the odds
45 ratio (OR). Survival probability was expressed as hazard ratios (HR) calculated through the
46 inverse variance method. The results were reported following the Preferred Reporting Items for
47 Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

48 **RESULTS:** This meta-analysis included 13 studies with 3,392 patients. There was no significant
49 difference in in-hospital mortality between HAR and TAR groups (OR 1.08; 95% CI 0.78-1.49; p
50 = 0.630). However, HAR group showed a higher incidence of permanent neurological dysfunction
51 (PND) (OR 1.71; 95% CI 1.22-2.41; $p < 0.001$). In subgroup meta-analysis with isolated type A
52 aortic dissection (ITAAD), HAR showed significantly lower in-hospital mortality ($p = 0.040$) but no
53 difference in PND. Other post-operative complications were significantly lower in the HAR group
54 for renal failure (OR 0.65; 95% CI 0.49-0.87; $p < 0.001$), sternal re-entry due to bleeding (OR
55 0.55; 95% CI 0.34-0.89; $p = 0.010$), and tracheostomy (OR 0.61; 95% CI 0.38-0.96; $p = 0.030$).
56 There is no statistical difference in 3-year survival probability (HR 0.97; 95% CI 0.70-1.35; $p =$
57 0.870).

58 **CONCLUSIONS:** TAR has more favorable than HAR in MDAD patients, offering lower rates of
59 neurological dysfunction and better 3-year freedom from re-intervention. For ITAAD patients, HAR
60 potentially provides better in-hospital mortality and 3-year survival rates, with fewer complications
61 such as renal failure, re-sternotomy, and tracheostomy.

62 Key Words

63 Hybrid arch repair; TEVAR; Total arch replacement; Outcome; Endovascular; Aortic arch; Aortic
64 dissection

65

66

67

68

69

70

71

72

73

74 INTRODUCTION

75 The most common aortic arch pathology is atherosclerosis, followed by other conditions such as
76 aortic dissection(1, 2). Total arch replacement (TAR) is an aggressive and high-risk surgical
77 procedure. The aim of the surgical treatment for chronic aortic aneurysms is to prevent aortic
78 rupture or dissection and to reduce the incidence of serious postoperative complications such as
79 death, permanent neurological dysfunction, acute renal failure, and tracheostomy. Moreover, the
80 procedure assigned to the patients should effectively improve the long-term survival probability
81 and reduce the risk of disability(3, 4).

82 Due to postoperative morbidity and mortality, less invasive treatment options such as
83 thoracic endovascular repair (TEVAR) with aortic arch surgical debranching or hybrid arch repair
84 (HAR)(3) are introduced for selected patients who are elderly or not fit for TAR.

85 In 2024, the European Association for Cardio-Thoracic Surgery (EACTS) and the Society
86 of Thoracic Surgeons (STS) guideline(5), there is an increasing trend for adopting TEVAR with
87 HAR as an option in complex arch aneurysms or acute type A aortic dissections(6-8). The risks
88 and benefits of HAR compared to TAR for the treatment of TAAD remain under debate(8-10).

89 Currently, TAR is the standard treatment for patients with aortic arch aneurysms or TAAD.
90 The individualized selection strategy for surgical treatment options remains controversial due to
91 a lack of solid data comparing various strategies(5). There have been no randomized controlled
92 trials comparing the outcomes of different treatments. Most studies on the outcomes of HAR
93 versus TAR are based on observational data.

94 Therefore, we conducted a meta-analysis to compare the early clinical outcomes and
95 intermediate-term survival of patients with aortic arch aneurysms or TAAD undergoing TAR or
96 HAR. The included studies were matched by propensity scores in order to reduce selection bias.

97 **METHODS**

98 Systematic review was conducted by accordance with the Preferred Reporting Items for
99 Systematic Reviews and Meta-Analysis (PRISMA) guidelines outlined by Page et al.(11).

100 **Population, Intervention, Comparison, and outcome (PICO)**

101 Using the PICO framework, as described by Richardson et al.(12), the research question was
102 addressed through this analysis as follows:

- 103 • **Population:** This includes any patients diagnosed with an aortic arch aneurysm or acute
104 and chronic aortic dissections involving the aortic arch that required repair. The repair
105 method used was debranching combined with thoracic endovascular aortic repair. These
106 patients were subsequently matched with similar patient characteristics within the studies
107 to those who had undergone conventional total arch replacement (in retrospective cohort
108 studies where propensity score matching occurred).
- 109 • **Intervention:** any patients indicated for hybrid arch debranching repair.
- 110 • **Comparison:** any patients indicated for total arch replacement whose characteristics
111 matched those of the intervention group.
- 112 • **Outcomes:** outcome measures were divided into:
 - 113 ○ *Early outcome measures:* These included in-hospital mortality, permanent
114 neurological dysfunction or stroke, renal failure, sternal re-entry due to bleeding,
115 and tracheostomy, all considered as odds ratio (OR).
 - 116 ○ *Intermediate term outcome measure:* These included 3-year and 5-year survival
117 probability, as well as 3-year and 5-year freedom from re-intervention as hazard
118 ratio (HR)

119 **Search strategy**

120 In April 2024, we conducted a search for studies related to this topic across multiple databases,
121 including PubMed, Embase, Cochrane Library, and Google Scholar. We also performed a manual
122 search for references from published studies that met the criteria of this study. The search
123 encompassed all fields under the following headings: "hybrid arch" AND "total arch" AND
124 "outcome" AND "aneurysm," using medical subject headings (MeSH Terms). These terms were
125 connected by the Boolean operator 'AND'. The search was not limited by language or publication
126 year. Initially, the titles of retrieved studies were screened, followed by a thorough evaluation of
127 the study abstracts and full texts to identify studies suitable for inclusion.

128 **Eligible criteria**

129 Studies were considered eligible if they met the following inclusion criteria: (1) studies to be
130 prospective observation or retrospective cohort with propensity-matched design, (2) studies to be
131 comparison of outcome in adult patients aged more than 18 years, (3) studies had to reported for
132 early and intermediate outcomes. Studies were excluded if satisfied any one of the following
133 exclusion criteria: (1) studies where participants were not propensity score matched, (2) case
134 report, correspondence, perspective or review article, (3) no arch involvement, and (4)
135 thoracoabdominal aortic aneurysm involvement.

136

137 **Data extraction and quality assessment**

138 The literature search was conducted by two independent reviewers (NK and NP) using pre-
139 designed search strategies. Duplicate studies were manually removed. Each reviewer
140 systematically screened titles, abstracts, and, where necessary, full texts to identify studies that
141 met the inclusion criteria. Data from the retrieved manuscripts—including study information,
142 design, patient demographics, treatment details, and early and intermediate outcomes—were
143 extracted. The risk of bias was assessed according to the Cochrane Handbook for Systematic

144 Reviews of Interventions(13), using the Risk of Bias in Non-randomized Studies of Interventions
145 (ROBINS-I) tool(14).

146 **Statistical analysis**

147 The data reported as medians with interquartile ranges were estimated using the Hozo et al.
148 approximation(15). Age was pooled using a fixed effects model to estimate the mean weighted in
149 both groups. Descriptive statistics were primarily used to determine associations in patient
150 characteristics between HAR and TAR using exact tests and independent t-tests, as appropriate.
151 Early surgical outcomes were expressed as odds ratios (OR) for binary outcomes, and effect
152 sizes for two-group comparisons were computed using a random effects model with the restricted
153 maximum-likelihood method. The outcome of different surgical option on survival outcomes and
154 freedom from re-intervention were measure as hazard ratio (HR), if HR not available, the data
155 were extracted from Kaplan-Meier curve using WebPlotDigitizer (available from:
156 <https://automeris.io/WebPlotDigitizer>) then calculate the HR with 95% confidence interval (CI)
157 using survival probabilities at difference time intervals from the survival curve and the number of
158 patients at-risk in each time intervals. The HR was transformed to natural logarithm before
159 aggregating by inverse variance method, then expressed as the HR with 95%CI in the forest
160 plot(16-18). Subgroup meta-analyses were performed in order to explore causes of heterogeneity.
161 Subgroups were categorized based on the study population domain, including studies reporting
162 outcomes for isolated type A aortic dissections (ITAAD) and mixed degeneration and dissection
163 (MDAD) arch pathology. The symmetry in funnel plots was used to evaluate publication bias.
164 Leave-one-out sensitivity analysis was used to assess robustness of the synthesized results. All
165 tests were two-tailed, with a significance level set at $p < 0.05$. Descriptive statistics, meta-analysis,
166 and chart creation were facilitated by STATA statistical software, version 17 (Stata Corp, College
167 Station, Texas) and Microsoft Excel (Microsoft Corp., Redmond, Washington).

168

169 **RESULTS**

170 **Literature search and study characteristics**

171 The study selection process is outlined in Figure 1. A total of 387 articles were identified, with 97
172 records removed due to duplication and 266 excluded after screening. Additionally, 28 records
173 were excluded for not meeting the eligibility criteria: 19 were non-matching studies, 5 were
174 correspondence, review articles, or case reports, 3 did not involve the aortic arch, and 1 involved
175 a thoracoabdominal aortic aneurysm. The study characteristics and risk of bias assessment are
176 detailed in Table 1. All of the included studies are retrospective cohort design and adjust the
177 confounding factors using propensity score matching method. There is no one studies reporting
178 the missing data in the cohort; these are risks for reporting the effect size of missing data. Seven
179 of thirteen studies(10, 19-24) presented a serious risk of bias, as they did not incorporate known
180 confounding factors, such as cerebrovascular disease or chronic renal failure, into the propensity
181 model (Table 1). Two of thirteen studies(25, 26) showed a serious risk of bias due to risk of
182 deviations from intended interventions and the classification of interventions. We rated nine out
183 of thirteen studies(10, 19-26) as having an overall serious risk of bias, while the remaining
184 studies(27-30) demonstrated a moderate overall risk. None of the studies had an overall low risk
185 of bias (Supplementary Figure 1), highlighting the inherent limitations of non-randomized studies.

186 **Patient characteristics**

187 A total number of 3,392 patients was included in the studies, with 1,696 patients in each group,
188 matched using the propensity score model (Table 2). The mean age for the HAR and TAR group
189 were 74.67 ± 14.17 and 74.38 ± 13.05 , respectively. There was no statistical difference between
190 the means of ages both groups ($p = 0.535$). In the present study, the percentage of males in the
191 HAR group (75.9%) and the TAR group (75.2%) showed no statistically significant difference (p
192 = 0.689). The proportion of urgent and emergency operations was 27.2% in the HAR group and

193 29.8% in the TAR group, with no statistically significant difference ($p = 0.363$). There was no
194 statistically significant difference in the prevalence of underlying diseases, such as hypertension,
195 diabetes mellitus (DM), coronary artery disease (CAD), previous myocardial infarction (MI),
196 chronic obstructive pulmonary disease (COPD), and renal failure.

197 **Early outcome**

198 *Early mortality analysis*

199 All 12 studies were included in a meta-analysis of in-hospital mortality. Forrest plots were
200 calculated and revealed no heterogeneity ($I^2 = 0\%$). The overall data showed no significant
201 difference in in-hospital mortality between HAR and TAR groups (OR 1.08; 95% CI 0.78-1.49; p
202 = 0.630) (Figure 2). In the MDAD and ITAAD subgroup meta-analysis showed no significant
203 difference in in-hospital mortality between the two groups ((OR 1.20; 95% CI 0.86-1.68) and (OR
204 0.36; 95% CI 0.12-1.07) respectively). A test for subgroup differences revealed a statistically
205 significant difference between the two groups ($p = 0.040$) (Figure 2). Publication bias was
206 assessed using a funnel plot (Supplementary Figure 1) along with regression-based Egger's test
207 ($p = 0.653$) and Begg's test ($p = 0.631$), both indicating no significant publication bias. The leave-
208 one-out sensitivity analysis confirmed that the results were robust and not significantly affected
209 by the exclusion of any single study (Supplementary Figure 2).

210 *Permanent neurological dysfunction and other post-operative complications*

211 The incidence on permanent neurological dysfunction (PND) or stroke showed a higher trend in
212 patients undergoing HAR compared to those in the TAR group (OR 1.71; 95% CI 1.22-2.41; p
213 <0.001; $I^2 = 0\%$). However, the subgroup meta-analysis for ITAAD studies found no statistically
214 significant difference in this outcome (Figure 3).

215 Other pooled post-operative complication results were found, a lower occurrence of renal
216 failure in the HAR group compared to the TAR group (OR 0.65; 95% CI 0.49-0.87; $p < 0.001$; $I^2 =$

217 0%) (Supplementary Figure 3). A lower occurrence of sternal re-entry due to bleeding was
218 observed in the HAR group compared to the TAR group (OR 0.55; 95% CI 0.34-0.89; $p = 0.010$,
219 $I^2 = 0\%$) (Supplementary Figure 4). Similarly, a lower occurrence of tracheostomy was observed
220 in the HAR group compared to the TAR group (OR 0.61; 95% CI 0.38-0.96; $p = 0.030$; $I^2 = 6.80\%$)
221 (Supplementary Figure 5).

222 **Intermediate term survival rate**

223 Ten studies were included(10, 19-23, 27-30), comprising 1130 patients, stratified as 565 pairs-
224 matched in each group. The pooled results for the 3-year survival probability showed no statistical
225 difference between the HAR and TAR groups (HR 0.97; 95% CI 0.7-1.35, $p = 0.870$, $I^2 = 46.75\%$)
226 (Figure 4). In the ITAAD subgroup, the 3-year survival probability was more favorable for HAR
227 (HR 0.36; 95% CI 0.16-0.79; $I^2 = 7.52\%$). Conversely, in the MDAD subgroup, there was no
228 statistically significant difference in the hazard ratio between the HAR and TAR groups (HR 1.21;
229 95% CI 0.84-1.73; $I^2 = 15.06\%$) (Figure 4). The test for subgroup differences indicates a
230 statistically significant result ($p = 0.010$), suggesting that type A aortic dissection is significantly
231 modified the effect of HAR compared to TAR.

232 Only four studies(10, 21, 22, 28) reported the 5-year survival outcome. The pooled result
233 showed a more favorable outcome in the TAR group compared to the HAR group, but this
234 difference was not statistically significant. (HR 1.29; 95% CI 0.81-2.05; $p = 0.280$; $I^2 = 53.25\%$)
235 (Supplementary Figure 6).

236 **Freedom from re-intervention probability**

237 Five studies(19, 21, 22, 28, 29) were included, comprising 606 patients stratified as 303 pair-
238 matched in each group. The overall result for the 3-year freedom from re-intervention indicated a
239 significantly higher rate of re-intervention in the HAR group compared to the TAR group (HR 3.69;
240 95% CI 1.97-6.90; $p < 0.001$; $I^2 = 31.16\%$) (Figure 5). At the 5-year follow-up, three studies(21,

241 22, 28) reported outcomes, also showing a higher rate of re-intervention in the HAR group (HR
242 4.39; 95% CI 2.31-8.34; $p < 0.001$; $I^2 = 0\%$), with no heterogeneity among the studies
243 (Supplementary Figure 7).

244 **DISCUSSION**

245 The primary outcome of our analysis indicated no overall difference in in-hospital mortality across
246 all studies. However, subgroup analysis revealed a statistically significant difference between the
247 overall in-hospital mortality and subgroup involving ITAAD studies ($p = 0.040$). In fact, our data
248 suggested some pattern that could have been indicative of trend in-hospital mortality benefit
249 among ITAAD patients undergoing HAR compared to TAR (OR 0.36; 95% CI 0.12-1.07). This
250 finding was consistent with previous studies(23, 24, 30), on patients with ITAAD undergoing Type
251 II hybrid debranching, as proposed by Bavaria et al. (31). The propensity-matched cohort studies
252 showed that in-hospital mortality ranged from 1.7% and 7.7% in the patients with HAR and 2.5%
253 to 23.1% in patients with TAR(23, 24, 30), regardless of whether they had undergone a frozen
254 elephant trunk procedure. In our study results, in-hospital mortality is comparable to the study
255 reported by Bavaria et al. for Type I and Type II HAR in patients with aortic arch aneurysms(31).

256 Our analysis estimated the odds ratio of PND following HAR versus TAR. In studies
257 involving MDAD aortic pathologies, there was a significantly higher occurrence of stroke in the
258 HAR group compared to the TAR group (OR 1.71; 95% CI 1.22-2.41; $p < 0.001$). This indicates a
259 statistical significant difference in stroke occurrence between the two groups. This finding was
260 consistent with literature from studies by Iba et al. (19) and Hiroaka et al.(20), which also reported
261 higher risk of stroke in the HAR. However, no significant difference was found in the subgroup of
262 study involving ITAAD. In contrast, Eleshra et al.(32) reported stroke rates of 14% in patients with
263 degenerative aneurysms and 2% in patients with aortic dissection. Huang F et al.(24) reported a

264 lower occurrence of stroke in HAR among patients with ITAAD, although these findings were not
265 statistically significant (OR 0.13; 95% CI 0.01-2.63).

266 Our study also revealed a statistically significant reduction in the occurrence of renal
267 failure (OR 0.65; 95% CI 0.49-0.87; $p < 0.001$), sternal re-entry due to bleeding (OR 0.55; 95%
268 CI 0.34-0.89), and tracheostomy (OR 0.61; 95% CI 0.38-0.96). These results aligned with findings
269 from most other studies(21, 26-28). A large non-propensity matched cohort study by Wallen et
270 al.(33) reported lower rate of mortality, stroke, paralysis, and renal failure rates in the TAR group,
271 this highlighting the potential influence of selection bias, as the TAR group tended to include
272 younger patients with fewer cases of peripheral arterial disease, and less preoperative
273 hemodialysis.

274 We reported a pooled 3-year survival probability between HAR and TAR, with no
275 statistically significant difference (HR 0.97; 95% CI 0.70-1.35). However, significant differences
276 were observed between the overall result and the ITAAD subgroup. These meta-analyses also
277 suggested a trend that ITAAD may benefit from HAR, but further evidence is needed to support
278 this hypothesis.

279 The rate of re-intervention at 3 years was significantly higher in the HAR group (HR 3.69;
280 95% CI 1.97-6.89, $p < 0.001$), suggesting inferior intermediate outcomes compared to TAR in
281 terms of freedom from re-intervention. However, in the subgroup of ITAAD, HAR showed a
282 significantly lower re-intervention rate than TAR. The 5-year survival possibility favored of the
283 TAR group, but the difference was not statistically significant, likely due to the limited number of
284 patients and propensity score–matched studies.

285 Recently, Spath et al.(34) published a meta-analysis that pooled outcomes of aortic arch
286 repairs involving endovascular techniques for chronic dissections, degenerative aneurysms,
287 penetrating aortic ulcers, and pseudoaneurysms. The overall technical success rate was 95.5%,

288 with an overall 30-day mortality rate of 6.7%. These outcomes may be comparable to those in
289 unmatched cohorts for the HAR group, which reported mortality rates ranging from 2.9% to
290 11.1%(21, 24, 26-28). The study highlighted that data on immediate to long-term outcomes from
291 total endovascular repairs are limited, raising questions about the durability of endovascular
292 grafts.

293 The results from prior single-center research may be constrained by several factors
294 including sample size, surgeon experience, and surgical preference, all of which contribute to
295 selection bias, a major confounding factor. These factors may make it challenging to estimate the
296 therapeutic effects of HAR. Although bias can be minimized by using propensity score matching
297 (35), small studies may still lack of statistical power required for demonstrating accurate
298 results(36). The information obtained from this meta-analysis can be useful to determine the
299 therapeutic effects of HAR compared to conventional TAR. The allocation of surgical procedures
300 among patients with various aortic arch pathologies or within distinct subgroups may be guided
301 by these results.

302 **Implication of this study**

303 Our study is the first systematic review and meta-analysis to estimate treatment outcomes
304 between HAR and TAR, specifically focusing on reducing selection bias by including only
305 propensity-score matched studies. The choice of surgical treatment for aortic arch pathologies
306 remain a crucial part.

307 The results suggest that for non-Type A Aortic Dissection pathologies, TAR may be more
308 beneficial compared to HAR due to a lower incidence of permanent neurological dysfunction and
309 a higher freedom from re-intervention at 3 years. On the other hand, in patients with Type A Aortic
310 Dissection, HAR may be considered due to the fact that it can reduce in-hospital mortality and
311 offer benefits to improve 3-year survival rates. Additionally, HAR may help reduce the incidence

312 of postoperative complications such as renal failure, re-sternotomy for bleeding, and
313 tracheostomy.

314 **Limitation**

315 A major limitation of this meta-analysis was incomplete reporting of missing data across the
316 analyzed retrospective cohorts. Therefore, this omission may introduce some biases, leading to
317 an under- or overestimation of the effect size or making it appear falsely precise. Furthermore,
318 the details in the characteristics of aneurysm and the entry site of dissection were not present in
319 enrolled studies. Such details are necessary to assess the applicability of the surgical results to
320 different patient subgroups and may impact the generalizability of our conclusions.

321 Furthermore, long-term follow-up of surgical interventions, particularly those using
322 propensity score-matched cohorts, is critically needed. Long-term studies are essential to
323 understand the durability and long-term effectiveness of these treatments. Future research should
324 focus on large prospective observational studies, propensity score matching, or randomized
325 controlled trials. These approaches are crucial for obtaining less biased estimates of the effects
326 of surgical interventions and for validating the results of our meta-analysis.

327 Finally, the development of an algorithm using individual patient data to guide the choice
328 of surgical procedures is essential. This approach aims to optimize the allocation of surgical
329 treatments based on specific clinical characteristics and conditions, maximizing the benefits for
330 patients.

331 **CONCLUSIONS**

332 This meta-analysis is the first study to critically evaluate and compare the outcomes of HAR and
333 TAR while using propensity score-matched studies, particularly to reduce selection bias. Our
334 findings suggest that TAR may be more favorable than HAR for MDAD studies, as it is associated

335 with lower rates of permanent neurological dysfunction and better 3-year freedom from re-
336 intervention, while showing similar in-hospital mortality and 3-year survival rates. Conversely,
337 HAR appears to offer advantages for ITAAD patients, potentially leading to lower in-hospital
338 mortality, improved 3-year survival, and reduced incidences of renal failure, re-sternotomy due to
339 bleeding, and tracheostomy.

340 **Acknowledgement**

341 We would like to express our sincere gratitude to all the researchers and clinicians who
342 contributed the studies included in this meta-analysis. Their work has been advancing our
343 understanding of the outcome of surgical intervention in different aortic arch pathologies. We also
344 thank the Suranaree University of Technology, Mahidol University, and Chiang Mai University for
345 their support throughout this research process, and the Royal College of Surgeons of Thailand
346 through research funding to present at Lisbon, Portugal. Additionally, we are grateful to our
347 colleagues for their insightful comments and suggestions that helped improve this manuscript.

348 **Funding**

349 None

350

351 **Author contributions statement**

352 **Naritsaret Kaewboonlert:** Contributed to all parts of the research. **Punthiti Pleehachinda** and
353 **Tossapol Prapassaro:** Writing, Review and Editing. **Natthipong Pongsuwan:** Conceptualized,
354 Writing, Review and Editing. **Worawong Slisatkorn** and **Apichat Tantraworasin:** Writing,
355 Review and Editing. **Chanut Chatkaewpaisal** and **Tummarat Ruangpratyakul:** Review and
356 Editing.

357 **Data Available Statement**

358 All data that support the finding of this meta-analysis are available from the corresponding
359 author upon reasonable request.

360

361 **Figure Legends**

362 **Figure 1.** PRISMA flow diagram shows the systematic review process.

363 **Figure 2.** Forest plot showing the results of in-hospital mortality after HAR versus TAR with the
364 subgroup meta-analysis in ITAAD and MDAD aortic arch pathologies.

365 HAR: Hybrid Arch Repair; TAR: Total Arch Replacement; ITAAD: Isolated Type A Aortic Dissection;
366 MDAD: Mixed Degeneration And Dissection.

367 **Figure 3.** Forest plot showing the results of permanent neurological dysfunction after HAR
368 versus TAR with the subgroup meta-analysis in ITAAD and MDAD aortic arch pathologies.

369 PND: Permanent Neurological Dysfunction; HAR: Hybrid Arch Repair; TAR: Total Arch Replacement;
370 ITAAD: Isolated Type A Aortic Dissection; MDAD: Mixed Degeneration And Dissection.

371 **Figure 4.** Forest plot showing the results of 3-year survival probability after HAR versus TAR
372 with the subgroup meta-analysis in ITAAD and MDAD aortic arch pathologies.

373 HAR: Hybrid Arch Repair; TAR: Total Arch Replacement; ITAAD: Isolated Type A Aortic Dissection;
374 MDAD: Mixed Degeneration And Dissection.

375 **Figure 5.** Forest plot showing the results of 3-year freedom from re-intervention after HAR
376 versus TAR.

377 HAR: Hybrid Arch Repair; TAR: Total Arch Replacement.

378

379

380

381

382

Tables

383 **Table 1.** Characteristics of studies included in this systematic review with risk of bias

384 assessment.

Author	Year	Country	Study size (n)	Pathology	HAR Bypass technique	ROBINS-I
Iba Y(19)	2014	Japan	70	MDAD	Extra-anatomic	Serious
Preventza O(27)	2015	United state	50	MDAD	Anatomic	Moderate
Tokuda Y(25)	2016	Japan	76	MDAD	Anatomic	Serious
Hiraoka A(20)	2017	Japan	86	MDAD	Extra-anatomic	Serious
Hori D(21)	2017	Japan	116	MDAD	Extra-anatomic	Serious
Yoshitake A(22)	2017	Japan	144	MDAD	Extra-anatomic	Serious
Ma M(23)	2018	China	52	ITAAD	Anatomic	Serious
Joo HC(28)	2019	South Korea	96	MDAD	Anatomic	Moderate
Seike Y(10)	2019	Japan	100	MDAD	Anatomic	Serious
Liu Y(29)	2021	China	180	MDAD	Anatomic	Moderate
Huang F(24)	2022	China	70	ITAAD	Anatomic	Serious
Liu S(30)	2023	China	236	ITAAD	Anatomic	Moderate
Oishi Y(26)	2024	Japan	2116	MDAD	Not report	Serious

385 Abbreviations: ROBINS-I, risk of bias in non-randomized studies: ITAAD, isolated type A aortic
386 dissection: MDAD, mixed degeneration and dissection: TEVAR, thoracic endovascular aortic
387 repair

388

389 **Table 2.** Summary of clinical characteristics reported in the included studies, presented as
390 mean \pm standard deviation or frequency and percentage.

Characteristics	Number of patients	HAR	Number of patients	TAR	p-value
Age, year	1696	74.67 \pm 14.17	1696	74.38 \pm 13.05	0.535
Male gender	1696	1287 (75.9)	1696	1276 (75.2)	0.689
Hypertension	1536	1261 (82.1)	1536	1274 (82.9)	0.569
Diabetic mellitus	1536	275 (17.9)	1536	274 (17.8)	1.000
Coronary artery disease or previous myocardial infarction	404	114 (28.2)	404	104 (25.7)	0.476
Chronic obstructive pulmonary disease	1638	178 (10.9)	1638	172 (10.5)	0.822
Renal failure	1603	181 (11.3)	1603	162 (10.1)	0.304
Urgent or emergency operation	580	158 (27.2)	580	173 (29.8)	0.363

391 Abbreviations: HAR, hybrid arch repair; TAR, total arch replacement
392

393 REFERENCES

- 394 1. Mestres CA, Greco E, Madrid CG, Pomar JL. The ability of Salmonella to drill holes in
395 the aorta. *Eur J Cardiothorac Surg.* 2002;22(1):145.
- 396 2. Koechlin L, Schuerpf J, Bremerich J, Sommer G, Gahl B, Reuthebuch O, et al. Acute
397 aortic dissection with entry tear at the aortic arch: long-term outcome. *Interact Cardiovasc*
398 *Thorac Surg.* 2021;32(1):89-96.
- 399 3. Tsagakis K, Pacini D, Grabenwöger M, Borger MA, Goebel N, Hemmer W, et al. Results
400 of frozen elephant trunk from the international E-vita Open registry. *Ann Cardiothorac Surg.*
401 2020;9(3):178-88.
- 402 4. Shrestha M, Martens A, Kaufeld T, Beckmann E, Bertele S, Krueger H, et al. Single-
403 centre experience with the frozen elephant trunk technique in 251 patients over 15 years. *Eur J*
404 *Cardiothorac Surg.* 2017;52(5):858-66.
- 405 5. Czerny M, Grabenwoger M, Berger T, Aboyans V, Della Corte A, Chen EP, et al.
406 EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of the aortic
407 organ. *Eur J Cardiothorac Surg.* 2024;65(2).
- 408 6. Rong D, Zhang H, Guo W. Aortic arch aneurysm isolated by percutaneous total
409 endovascular arch replacement. *Eur Heart J.* 2022;43(30):2905.
- 410 7. Gouveia EMR, Stana J, Prendes CF, Kölbl T, Peterss S, Stavroulakis K, et al. Current
411 state and future directions of endovascular ascending and arch repairs: The motion towards an
412 endovascular Bentall procedure. *Semin Vasc Surg.* 2022;35(3):350-63.
- 413 8. Castrovinci S, Pacini D, Di Marco L, Berretta P, Cefarelli M, Murana G, et al. Surgical
414 management of aortic root in type A acute aortic dissection: a propensity-score analysis. *Eur J*
415 *Cardiothorac Surg.* 2016;50(2):223-9.
- 416 9. Beckmann E, Martens A, Kaufeld T, Natanov R, Krueger H, Haverich A, et al. Is total
417 aortic arch replacement with the frozen elephant trunk procedure reasonable in elderly patients?
418 *Eur J Cardiothorac Surg.* 2021;60(1):131-7.
- 419 10. Seike Y, Matsuda H, Fukuda T, Hori Y, Inoue Y, Omura A, et al. Is debranching thoracic
420 endovascular aortic repair acceptable as the first choice for arch aneurysm in the elderly?
421 *Interact Cardiovasc Thorac Surg.* 2019;29(1):101-8.
- 422 11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
423 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.*
424 2021;372:n71.
- 425 12. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question:
426 a key to evidence-based decisions. *ACP J Club.* 1995;123(3):A12-3.
- 427 13. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. *Cochrane*
428 *Handbook for Systematic Reviews of Interventions* version 6.4 (updated August 2023):
429 *Cochrane*; 2023.
- 430 14. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al.
431 ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ.*
432 2016;355:i4919.
- 433 15. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median,
434 range, and the size of a sample. *BMC Med Res Methodol.* 2005;5:13.
- 435 16. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses
436 of the published literature for survival endpoints. *Stat Med.* 1998;17(24):2815-34.
- 437 17. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with
438 time-to-event outcomes. *Stat Med.* 2002;21(22):3337-51.
- 439 18. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for
440 incorporating summary time-to-event data into meta-analysis. *Trials.* 2007;8:16.

- 441 19. Iba Y, Minatoya K, Matsuda H, Sasaki H, Tanaka H, Oda T, et al. How should aortic arch
442 aneurysms be treated in the endovascular aortic repair era? A risk-adjusted comparison
443 between open and hybrid arch repair using propensity score-matching analysis. *Eur J*
444 *Cardiothorac Surg*. 2014;46(1):32-9.
- 445 20. Hiraoka A, Chikazawa G, Totsugawa T, Tamura K, Ishida A, Sakaguchi T, et al.
446 Objective analysis of midterm outcomes of conventional and hybrid aortic arch repair by
447 propensity-score matching. *J Thorac Cardiovasc Surg*. 2017;154(1):100-6 e1.
- 448 21. Horii D, Okamura H, Yamamoto T, Nishi S, Yuri K, Kimura N, et al. Early and mid-term
449 outcomes of endovascular and open surgical repair of non-dissected aortic arch aneurysm.
450 *Interactive CardioVascular and Thoracic Surgery*. 2017;24(6):944-50.
- 451 22. Yoshitake A, Okamoto K, Yamazaki M, Kimura N, Hirano A, Iida Y, et al. Comparison of
452 aortic arch repair using the endovascular technique, total arch replacement and staged
453 surgery†. *Eur J Cardiothorac Surg*. 2017;51(6):1142-8.
- 454 23. Ma M, Feng X, Wang J, Dong Y, Chen T, Liu L, et al. Acute Type I aortic dissection: a
455 propensity-matched comparison of elephant trunk and arch debranching repairs. *Interact*
456 *Cardiovasc Thorac Surg*. 2018;26(2):183-9.
- 457 24. Huang F, Li X, Zhang Z, Li C, Ren F. Comparison of two surgical approaches for acute
458 type A aortic dissection: hybrid debranching versus total arch replacement. *J Cardiothorac Surg*.
459 2022;17(1):166.
- 460 25. Tokuda Y, Oshima H, Narita Y, Abe T, Araki Y, Mutsuga M, et al. Hybrid versus open
461 repair of aortic arch aneurysms: comparison of postoperative and mid-term outcomes with a
462 propensity score-matching analysis. *Eur J Cardiothorac Surg*. 2016;49(1):149-56.
- 463 26. Oishi Y, Kumamaru H, Kato M, Ohki T, Shiose A, Motomura N, et al. Open Versus Zone
464 0/1 Endovascular Aortic Repair for Arch Aneurysm: A Propensity Score-Matched Study from the
465 National Clinical Database in Japan. *Ann Vasc Surg*. 2024;100:128-37.
- 466 27. Preventza O, Garcia A, Cooley DA, Haywood-Watson RJ, Simpson K, Bakaeen FG, et
467 al. Total aortic arch replacement: A comparative study of zone 0 hybrid arch exclusion versus
468 traditional open repair. *J Thorac Cardiovasc Surg*. 2015;150(6):1591-8; discussion 8-600.
- 469 28. Joo HC, Youn YN, Kim JH, Lee SH, Lee S, Yoo KJ. Conventional Open Versus Hybrid
470 Arch Repair of Aortic Arch Disease: Early and Long-Term Outcomes. *Ann Thorac Surg*.
471 2019;107(5):1380-8.
- 472 29. Liu Y, Liang S, Zhang B, Dun Y, Guo H, Qian X, et al. Type II hybrid arch repair versus
473 total arch replacement with frozen elephant trunk: a propensity score-matched analysis. *Eur J*
474 *Cardiothorac Surg*. 2021;60(2):297-304.
- 475 30. Liu S, Qiu J, Qiu J, Jiang W, Gao W, Wei B, et al. Midterm Outcomes of One-Stage
476 Hybrid Aortic Arch Repair for Stanford Type A Aortic Dissection: A Single Center's Experience.
477 *Semin Thorac Cardiovasc Surg*. 2023;35(2):311-21.
- 478 31. Bavaria J, Vallabhajosyula P, Moeller P, Szeto W, Desai N, Pochettino A. Hybrid
479 approaches in the treatment of aortic arch aneurysms: postoperative and midterm outcomes. *J*
480 *Thorac Cardiovasc Surg*. 2013;145(3 Suppl):S85-90.
- 481 32. Eleshra A, Heo W, Lee KH, Kim TH, Sim SA, Sharafeldin H, et al. Mid-term outcomes of
482 hybrid debranching endovascular aortic arch repair in landing zones 0-2. *Vascular*.
483 2023;31(3):447-54.
- 484 33. Wallen T, Carter T, Habertheuer A, Badhwar V, Jacobs JP, Yerokun B, et al. National
485 Outcomes of Elective Hybrid Arch Debranching with Endograft Exclusion versus Total Arch
486 Replacement Procedures: Analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery
487 Database. *Aorta (Stamford)*. 2021;9(1):21-9.
- 488 34. Spath P, Campana F, Tsilimparis N, Gallitto E, Pini R, Faggioli G, et al. Outcomes of
489 Fenestrated and Branched Endografts for Partial and Total Endovascular Repair of the Aortic
490 Arch - A Systematic Review and Meta-Analysis. *Eur J Vasc Endovasc Surg*. 2024;67(1):106-16.

- 491 35. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a
492 treatment to a non-randomized control group. *Stat Med.* 1998;17(19):2265-81.
493 36. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of
494 Confounding in Observational Studies. *Multivariate Behav Res.* 2011;46(3):399-424.
495





Figure 1

In-hospital mortality



Random-effects REML model

1/32 1/2 8 128
 Favor HAR Favor TAR

Figure 2






Figure 3

Mixed Dissection and Degeneration




Isolated Type A Aortic Dissection



Overall

Heterogeneity: $I^2 = 46.75\%$, $H^2 = 1.88$
 Test of $\theta_i = \theta_j$: $Q(9) = 16.90$, $p = 0.05$
 Test of group differences: $Q_b(1) = 7.58$, $p = 0.01$




Fixed-effects inverse-variance model

Figure 4

3-year freedom from re-intervention
Study

Hazard ratio
with 95% CI
Weight
(%)



Heterogeneity: $I^2 = 31.16\%$, $H^2 = 1.45$
Test of $\theta_i = \theta_j$: $Q(4) = 5.81$, $p = 0.21$
Test of $\theta = 0$: $z = 4.08$, $p = 0.00$

1/16 1 16 256
Favor HAR Favor TAR

Fixed-effects inverse-variance model

Figure 5